Correvio Pharma (CORV)

[ctb]

CRME - Cardiome Pharma receives approval for BRINAVESS in South Africa (3.62)

VANCOUVER, Sept. 30, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that BRINAVESS™ (vernakalant intravenous) has been approved in South Africa by the Medicines Control Council (MCC) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The MCC oversees the regulation of medicines in South Africa.
"Cardiome is pleased with the approval of BRINAVESS in South Africa," said Karim Lalji, Cardiome's Chief Commercial Officer. "We are committed to partnering BRINAVESS in this important pharmaceutical market as we continue to focus Cardiome's direct sales efforts on key countries in Europe.